Mission Therapeutics
Mission Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer. The company holds and aims to maintain world-leadership in DNA repair and associated molecular mechanisms, particularly those involving enzymes of the ubiquitin pathway. Mission Therapeutics will use its knowledge and proven expertise in targeting these pathways for small-molecule drug discovery to develop new therapeutic agents with wide market potential. These drugs mainly target “Achilles heels” of diseased tissues by exploiting the concept of synthetic-lethality.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Live
Website
missiontherapeutics.com
Related News
Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease
Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury
Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.